Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

April 2, 2022

Study Completion Date

June 28, 2022

Conditions
Breast Cancer Female
Interventions
DRUG

Metformin Hydrochloride 850 mg Tablets

Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles

DRUG

AC-T chemotherapy regimen

AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.

Trial Locations (1)

22511

Damanhour University, Beheira

All Listed Sponsors
collaborator

Alexandria University

OTHER

lead

Damanhour University

OTHER

NCT04170465 - Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO) | Biotech Hunter | Biotech Hunter